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Abstract
Purpose—For classical Hodgkin lymphoma (HL), migrant studies could elucidate contributions 
of environmental factors (including Epstein–Barr virus (EBV)) to the lower rates in non-whites. 
Given the well-described etiologic complexity of HL, this research requires a large, immigrant 
population, such as California Hispanics.
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Methods—With 1988–2004 California Cancer Registry data (2,595 Hispanic, 8,637 white HL 
cases) and tumor cell EBV status on a subset (218 Hispanics, 656 whites), we calculated ethnicity- 
and nativity-specific HL incidence rates simultaneously by age, sex, and histologic subtype, and 
tumor cell EBV prevalence.
Results—Compared with white rates, Hispanic HL rates were lower overall (70 %) and for 
nodular sclerosis HL, particularly among young adults (60–65 % for females). However, they were 
higher among children (200 %) and older adults, and for mixed cellularity HL. Compared with 
rates in foreign-born Hispanics, rates in US-born Hispanics were higher among young adults 
(>threefold in females), lower for children and adults over age 70, and consistently intermediate 
compared with rates in whites. EBV tumor prevalence was 67, 32, and 23 % among foreign-born 
Hispanics, US-born Hispanics, and whites, respectively, although with variation by age, sex, and 
histology.
Conclusions—Findings strongly implicate environmental influences, such as nativity-related 
sociodemographic differences, on HL occurrence. In addition, lower young adult rates and higher 
EBV prevalence in US-born Hispanics than in whites raise questions about the duration/extent of 
environmental change for affecting HL rates and also point to ethnic differences in genetic 
susceptibility. Lesser variation in mixed cellularity HL rates and greater variation in rates for 
females across groups suggest less modifiable factors interacting with environmental influences.
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Introduction
Hodgkin lymphoma (HL) is an uncommon B-cell malignancy with marked epidemiologic 
heterogeneity across histologic subtypes and patient age, sex, and race/ethnicity. Studies 
have long supported socioeconomic influences on disease etiology for children and young 
adults [1–11]; risk factors include characteristics describing intensity and timing of 
childhood social exposure, and management of infection [12], notably Epstein–Barr virus 
(EBV), which is present in monoclonal form in tumor cells of an epidemiologically 
distinctive proportion of cases [13–16]. Yet, racial/ethnic differences in HL occurrence 
persist regardless of socioeconomic status (SES) [4, 17], with higher rates [18] and lower 
tumor EBV prevalence [13, 16] in whites. This variation suggests additional environmental 
[17, 19] and/or genetic influences [20–23].
These contributions to HL etiology could be explored efficiently through migrant studies, 
but the paucity of large immigrant cohorts for evaluating this rare and complex disease has 
limited such research [11, 17, 19–21]. US Hispanics represent an ideal study population: 
This is a large group with a substantial foreign-born subset, and US- and foreign-born 
Hispanics likely differ in relevant childhood infectious exposures and other immune system 
influences [22]. However, migrant studies of HL in US Hispanics have been impeded by 
methodologic challenges, including cultural and genetic heterogeneity [23–28], which can 
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dilute study findings, and missing cancer registry information on birthplace for a sizeable, 
non-random segment of cases, which may introduce bias into estimated rates [29–34].
To advance understanding of how environment affects HL incidence variation, we examined 
the effect of nativity on HL rates in US Hispanics in comparison with non-Hispanic whites, 
addressing the aforementioned challenges using California Cancer Registry (CCR) data, and 
nativity-specific numerators and denominators [35, 36] associated with the California 
Neighborhoods Data System [37]. This approach provided access to a Hispanic population 
that is large, relatively homogeneous culturally and ethnically (approximately 80 % of 
Mexican origin in 2001 [38]), and for which missing registry birthplace information for 
cases was imputed by a validated method [36, 39, 40]. In addition, as the association of 
tumor cell EBV with HL is strong in Hispanics [13, 41, 42] but not well studied by 
birthplace, we examined variation in its prevalence across a subset of study cases [16].
Materials and methods
Patient data
We identified all California residents newly diagnosed with primary classical HL 
(International Classification of Diseases for Oncology, 3rd Edition, morphology codes 
9663–9665, 9667 (nodular sclerosis (NS)); 9652 (mixed cellularity (MC)); 9651 
(lymphocyte rich); 9653–9655 (lymphocyte depletion), or 9650 (not otherwise specified)) 
during the period 1988 through 2004 and reported to the CCR. We obtained data (routinely 
abstracted from the medical record) on patient age, sex, race/ethnicity, social security 
number (SSN), birthplace, and tumor histology at diagnosis for all 2,754 HLs in Hispanics 
and 8,971 HLs in non-Hispanic whites (hereafter called whites). Hispanic status, based on 
patient medical records and death certificates, was enhanced using the North American 
Association of Central Cancer Registries (NAACCR) Hispanic Identification Algorithm 
[43]. Because HIV-related HL has unusual epidemiologic profiles and had increased rates in 
California Hispanics during the study period [44], we excluded 159 Hispanic (5.8 %) and 
334 white (3.7 %) HL cases with evidence of HIV or AIDS in registry diagnostic or death 
certificate data [45]. These exclusions left 2,595 Hispanic and 8,637 white HL cases for 
analysis.
Nativity—Of the 2,595 Hispanic cases, the CCR listed 1,054 (41 %) as US-born and 849 
(33 %) as having a foreign birthplace (Mexico (n = 571), Central America (n = 119), South 
America (n = 51), Cuba (n = 21), Puerto Rico (n = 14), other North America (n = 6), Europe 
(n = 8), Asia (n = 4), not US (n = 5), and unspecified (n = 50 with data from the death 
certificate)). Among the 692 cases (27 %) without a recorded birthplace, we applied a 
previously validated method using patient SSN (and presumed year of issuance) to impute 
nativity for 591 cases [36], and, for 101 cases with missing or invalid SSNs, assigned 
nativity based on its distribution within matched strata of race/ethnicity, sex, and age in the 
overall CCR Hispanic patient population. Ultimately, we categorized 531 Hispanic HL cases 
without registry birthplace as US-born, for a total of 1,585 (61 %), and 161 as foreign-born, 
for a total of 1,010 (39 %).
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EBV tumor status—For all incident HL cases diagnosed in 1988–1997 in selected 
California counties (non-whites only from southern California), we previously linked CCR 
data to results of tumor cell EBV assays applied to diagnostic specimens [16]. Reflecting 
regional variation in specimen-releasing practices, specimens were available from 86 % of 
Greater Bay Area cases and 43 % of southern California cases, and thus for 73 % of whites 
and 38 % of Hispanics. For these 219 Hispanic cases with EBV results, birthplace had not 
been recorded for 54 (25 %). For the current study, we determined nativity for 53 of these 
cases using the methods described above, thus enabling reanalysis in 218 Hispanic cases by 
nativity compared with 656 whites.
Population data
To compute incidence rates, we obtained California population counts from the 1990 and 
2000 Census Summary File 3 by sex, race/ethnicity, nativity, and 5-year age group. To 
estimate age- and nativity-specific population counts for Hispanics, we used the 5 % 
Integrated Public Use Microdata Series sample of the Census; for intercensal years, we 
estimated the percentages of the population that were US-or foreign-born using cohort 
component methods [36, 46].
Statistical analysis
Incidence rates and rate ratios—For the period 1988–2004, we computed average 
annual age-adjusted (standardized to the 2000 US standard million population) and age-
specific incidence rates per 100,000 population and associated 95 % confidence intervals 
(CI). To accommodate HL incidence patterns [47], we examined age-specific rates for 5-
year age groups (presented only in study figures), for 10-year age groups, and for age ranges 
0–14, 15–39, 40–54, and ≥55 years (hereafter called “children,” “adolescents/young adults 
(AYAs),” “middle-aged adults” and “older adults”). We calculated rates for classical HL 
overall and, based on sample size, for the two most common histology subtypes (NS and 
MC). For comparisons of pairs of incidence rates, we calculated incidence rate ratios (IRRs), 
considering as significant any difference for which the IRR 95 % CI did not include 1.
EBV prevalence by race/ethnicity and nativity—We examined the associations of 
age group, sex, and histologic subtype (NS, MC, and other) with EBV-positive and EBV-
negative HL in foreign-born Hispanics, US-born Hispanics, and whites using descriptive 
statistics. As EBV prevalence in HL varies markedly by these variables [13], we undertook 
multivariate analyses to determine whether they were independently associated with EBV-
positive HL by calculating prevalence ratios (PRs) and 95 % CIs, controlling for additional 
cofactors (census block group SES, Ann Arbor stage, and California residential region), as 
used previously [16].
Analyses were conducted using SEER*Stat software for incidence rates [48] and SAS 
version 9.3 for EBV prevalence [49]. This study had approval from the institutional review 
boards of the Cancer Prevention Institute of California and institutions collaborating on the 
previous study of HL and EBV [16].
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Results
Incidence rates
Hispanics—Among California Hispanics, the 1988–2004 age-adjusted HL incidence rate 
per 100,000 was 2.02 overall (Table 1). Figure 1a and b showed bimodal curves comprising 
modest modes in AYA males and females but considerably higher rate peaks in adults, 
particularly males, over age 70–74.
Hispanics versus whites—Compared with whites, Hispanics had overall HL rates that 
were approximately 30 % lower and showed a larger male excess (male–female (M–F) IRRs 
with 95 % CI: Hispanics, 1.39 (1.27–1.53); whites, 1.18 (1.13–1.23)), reflecting relatively 
lower female than male rates (Table 1). For NS, rates in Hispanics were half those in whites; 
for MC, they were slightly higher than in whites. Age-specific data (Fig. 1a–f) show that 
AYA incidence peaks were markedly lower in Hispanics than in whites for HL overall; for 
NS, peak rates (at ages 20–29) were higher in females than in males for both Hispanics (M–
F IRR: 0.70 (0.58–0.84)) and whites (M–F IRR: 0.84 (0.76–0.93)). For children and older 
adults, HL rates were higher for Hispanics than for whites, notably in males. For NS, similar 
patterns occurred, with higher rates in Hispanic than in white males, but not in females, 
under age 10 (M–F IRRs: Hispanics, 2.77 (1.64–4.87); whites, 1.21 (0.57–2.62)) and at ages 
80 and over. For MC, Hispanics had higher rates than whites in children and older adults of 
both genders.
Hispanics by nativity—HL incidence rates were higher in US- than in foreign-born 
Hispanics, 55 % for females and 22 % for males (Table 2). AYA rates were substantially 
higher in the US-born than in the foreign-born (Fig. 2a, b), approximately two times among 
males and more than three times among females. For NS (Fig. 2c, d), rates across age groups 
10–19 through 50–59 were up to 2.7 times higher in the US- than in the foreign-born for 
males and three to nearly five times higher for females, due to a female rate excess among 
the US-born. For MC (Fig. 2e, f), AYA rates were substantially higher in US- than in 
foreign-born Hispanics (fourfold for females at ages 20–29), although higher in males than 
in females in both the US-born (M–F IRR: 1.84 (1.21–2.87)) and foreign-born (M–F IRR: 
2.94 (1.65–5.56)). Among children ages 5–9, rates per 100,000 were lower in US-than in 
foreign-born Hispanics overall and for MC (0.14 and 0.58, respectively), while for NS, they 
were higher for US- than for foreign-born boys (0.52 and 0.26) and similar for girls (0.15 
and 0.19).
Whites, US-born and Foreign-born Hispanics—Overall HL rates were lower among 
both US-born and foreign-born Hispanics than whites (Table 3), although less so for the US-
born, notably females, for whom rates in US-and foreign-born Hispanics were 
approximately 80 and 50 % those of whites. In contrast, for children, HL rates were twofold 
higher among US-born Hispanics and fourfold higher among foreign-born Hispanics than 
whites; similar, but smaller, differences occurred for adults over age 70. For MC, rates were 
higher in Hispanics, irrespective of nativity, than in whites overall, although these 
differences were smaller for US-born than for foreign-born Hispanics. Among children, MC 
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rates in Hispanics were eightfold higher in the foreign-born and about 2.5-fold higher in the 
US-born than in whites.
EBV associations
Tumor cell EBV prevalences were highest in foreign-born Hispanics, followed by US-born 
Hispanics and whites, in almost every age, sex, and histology subtype group (Table 4). For 
children and older adults, EBV prevalences were relatively similar for foreign- and US-born 
Hispanics (albeit higher in the former), but much lower for whites. For AYAs, EBV 
prevalences were higher for foreign-born than for US-born Hispanics but similar for US-
born Hispanics and whites; however, this latter pattern was limited to females (EBV 
prevalences for males and females, respectively: 48 and 27 % in foreign-born Hispanics (n = 
25 male and 11 female HL cases), 35 and 11 % in US-born Hispanics (n = 37 and 38), and 
26 and 13 % in whites (n = 174 and 220)). Adjusted EBV PRs were increased for older 
adults versus AYAs and for MC versus NS in all three Hispanic/white groups, and for 
children versus AYAs in US- and foreign-born Hispanics. Adjusted EBV PRs for males 
versus females were higher for whites than for foreign-born and US-born Hispanics, 
reflecting the relatively low EBV prevalence in white women.
Discussion
This study is the first to examine HL incidence rates using a case series of US Hispanics 
whose large size, relative ethnic homogeneity, fully characterized birthplace, and tumor cell 
EBV status for a subset, permitted detailed insights into immigration-related differences in 
occurrence. Overall, the lower HL rates in Hispanics than in whites among AYAs, but higher 
rates in children and older adults (notably males), varied by nativity. Ethnic differences were 
quite marked in foreign-born Hispanics, particularly younger children, but attenuated for 
US-born Hispanics, especially for women and for the NS subtype. EBV prevalence in HL 
tumors declined from foreign-born Hispanics to US-born Hispanics to whites, more 
dramatically in AYA women than in other age–sex groups. Together, these patterns extend 
evidence for strong socioeconomically associated environmental influences on HL incidence 
and on its EBV-defined subtypes. They also support the hypothesis that HL results from age-
differing challenges to immune function [12], with higher risk in children exposed to 
intense, early infection, consistent with their larger family sizes [50]; higher risk in AYAs 
with delayed exposures to infection related to fewer childhood social contacts (e.g., fewer 
older siblings [51], less nursery school attendance [52]); and higher risk in older adults 
linked with more social contacts, likely because control of infection, especially with chronic 
herpesviruses, diminishes with immunosenescence. Beyond that, HL rate differences 
between US-born Hispanics and whites raise questions about the timing, duration, and/or 
extent of environmental change required to reduce ethnic variation in rates. Differences in 
nativity-specific variation for NS and MC underscore distinct etiologies. The markedly 
larger nativity effect on NS rates in AYA females than in males, but the lesser effect on rates 
for girls than for boys, illustrates the strong, age-varying influence of gender on NS HL 
occurrence.
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Previous studies reported lower overall HL rates in US Hispanics, especially in AYAs, but 
higher rates for children and older adults, although most studies did not have adequate 
sample sizes to calculate rates simultaneously by age, sex, and histologic subtype [3, 4, 11, 
17, 19, 53–55]. The three prior studies evaluating the effect of nativity on HL in Hispanics 
[11, 17, 19] lacked either the numbers of cases to stratify data by age, sex, and histologic 
subtype [17, 19], or nativity for all cases [11]; none included EBV information. In our study, 
nativity results generally resembled the prior findings. However, whereas Cozen et al. [17] 
showed higher NS rates in foreign- than in US-born Latinos under age 14 in Los Angeles 
County in 1972–1985, we observed no significant nativity differences at these ages, 
suggesting possible temporal or cohort changes in NS incidence. In SEER-wide data (2,067 
Hispanic cases from 1992–2007), Evens et al. [11] reported lower proportions of MC in the 
US- than in the foreign-born; in our study, the lack of difference in MC rates by nativity, 
likely reflecting adjustment for age differences between groups, indicates little impact of 
birthplace on overall incidence of this histologic subtype. Numerous studies of EBV-related 
HL have described higher tumor EBV prevalence in Hispanics than in whites [16, 41, 42, 
56–59]. Although none considered nativity, prevalences in our foreign-born cases were 
similar to those reported from Mexico and Costa Rica [42, 58].
As HL rates vary with economic conditions [1, 2, 4, 5, 7, 10, 17], some of the ethnic and 
nativity variation in rates reported here likely reflects socioeconomic differences. In 2001, 
California Hispanics differed from whites in having less education (74 vs. 31 % completing 
high school or less), more poverty (35 vs. 6 % living at or below the federal poverty level), 
and larger households (86 vs. 56 % with 3 or more persons) [60]—all characteristics 
associated with lower HL risk [1–11]. Similarly, foreign-born Hispanics differed from US-
born Hispanics in reporting less education (84 vs. 57 % completing high school or less) and 
more poverty (42 vs. 28 % living at or below the federal poverty level) [60]. These 
socioeconomic conditions likely reflect aspects of the timing and intensity of exposure to 
infection linked to HL risk [12]. In several studies, Mexican-Americans had higher 
seroprevalence and overall burdens of common, latent infections even after control for social 
class [61, 62], and earlier age at infection [63, 64] than whites, and foreign birthplace was an 
independent predictor of these associations [61–66]. For children, these findings may 
describe the early and intense infections assumed to predict higher HL risk and may help 
explain the higher HL rates in foreign-born Hispanic children. For AYAs, they may speak to 
a well-primed childhood immune system, particularly in the foreign-born, consistent with 
their much lower young adult HL rates [67]. For older adults, greater infectious disease 
burdens among Mexican-Americans, particularly the foreign-born [68], may relate to the 
increased HL rates in Hispanics compared with whites; specifically, higher antibody titers 
against latent herpesviruses in Hispanics [69] may reflect diminished immune function and 
poorer control of latent infection due to stress [68, 70–72], lower SES [61, 69, 72, 73], or 
related aspects of immigration [74, 75] that could be related to HL development.
EBV-positive HL tumors appear to result from an aberrant immune response to EBV 
infection due to abnormal immune function [25, 76, 77]. The higher EBV prevalence in 
tumors of foreign-born than US-born Hispanics than whites in our study, which recalls the 
higher EBV prevalence in HL in populations from developing than developed economies 
[13, 42, 57, 78–80], and in some but not other European populations [13], suggests that 
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foreign-born Hispanics have poorer immune control of EBV than US-born Hispanics and 
whites, particularly among children and older adults. For Hispanics, some data indirectly 
support this conjecture. In children and teenagers, adjusted PRs for EBV seroprevalence [81] 
and absolute antibody titers [81, 82] were higher in Mexican-Americans than whites, 
foreign- than US-born individuals, girls than boys, and children from lower versus the 
highest quartiles of household income [81]. In adults ages 24–32, EBV antibody titers were 
increased for Hispanics, females, and having lower SES during adolescence, suggesting 
long-lasting impacts of early environment on immune control of EBV [71]. EBV 
seroprevalence and antibody titers against lytic and latent antigens were higher in Mexicans 
than in Italians, Dutch, Israelis, Columbians, or Papua New Guineans [83], although a Texas 
community study found lower antibody titers against EBV lytic antigens in Hispanics than 
in whites [72]. Our finding of a lower EBV prevalence in HL tumors among US-than 
foreign-born Hispanics thus may reflect improved immune function as related to EBV 
control. However, given their higher HL rates, it also may reflect increased exposure to, or 
greater prevalence of, other environmental causes.
The deficit of AYA HL rates even in US-born Hispanics compared with whites in these data 
may diminish with increasing acculturation. In 2001, the California Hispanic population was 
still relatively recently immigrated (46 % foreign-born, 30 % residing in the US for under 10 
years [60]). Nevertheless, to date, no study of HL incidence has observed an equivalence of 
rates in immigrants to those in the host country or of rates in young adult non-whites with 
those in whites over time [10, 11, 20, 21, 84]. For His-panics, young adult HL rates did not 
change over the 1990s and 2000s in either the US- or foreign-born [11]. Thus, persistent 
differences in HL rates between US-born Hispanics and whites may in part also reflect less 
modifiable aspects of HL etiology, such as HLA genotype [85–88], which manifests racial/
ethnic variation in its association with HL overall [89] and by tumor cell EBV status [87]. 
Prevalence of the HLA-A2 allele, protective against EBV-positive HL [87, 90], varies across 
racial/ethnic groups, including Hispanics [87, 91, 92], and Mexican-Americans have specific 
HLA region determinants of immune response to EBV infection, including SNPs associated 
with HL [93].
The greater rate stability with immigration for the MC than for the NS subtypes in our data 
and the stronger association of EBV with MC irrespective of ethnicity and nativity support 
separate histology-specific etiologies [94] and, for MC, a larger component of invariable 
etiologic pathways across populations. Nevertheless, the nativity variation in MC rates also 
reveals environmental sensitivity in MC etiology, possibly through changes in immune 
function: Barros et al. [59] hypothesized that, as in HIV-related HL, EBV infection in 
children with poorer immune responses due to challenging environments may promote 
development of MC, while those with stronger immune function associated with healthier 
environments would develop NS. For NS, the higher rates in US- than in foreign-born AYAs, 
together with the lower EBV prevalences, confirm the view that EBV is not a dominant 
etiologic factor for this HL subtype [47]. However, as infectious mononucleosis, a strong 
risk factor for young adult EBV-associated HL [95, 96], seems less likely in US-born 
Hispanic AYAs than in whites in California, given their socioeconomic profiles [60], other 
pathways may lead to the observed higher EBV prevalences in HL in AYA US-born 
Hispanic males.
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The larger immigration-related variation in HL rates in females than in males may reflect 
acculturation-related exposures together with biologic differences. If hormonal exposures 
related to reproduction interact with exposures to children to affect HL risk in women [97], 
the greater HL rate variation by ethnicity and nativity among AYA females than males may 
reflect protection to Hispanic women from earlier and more intense household exposure to 
infection. Among California women ages 15–39 in 2001, 41 % of foreign-born Hispanics, 
17 % of US-born Hispanics, and 12 % of whites had had three or more children [60]. 
Among older men, the high HL rates in foreign-born than in US-born Hispanics might result 
in part from chronic inflammation from higher lifetime infection burdens [75].
Our findings are subject to some limitations. First, our inability to account for duration of 
US residence among foreign-born Hispanics, or degree of acculturation among US-born 
Hispanics, limits the precision of estimated rates and may bias our nativity-specific findings 
[17]. Second, although SES is a predictor of racial/ethnic differences in HL incidence [4, 13, 
16], we lacked the denominators to calculate nativity- and neighborhood-level SES-specific 
rates. Third, tumor cell EBV status was available only on a small proportion of cases, 
limiting statistical power. HL tumors not retrievable for EBV testing were more likely to be 
from cases that were non-white, male, and from southern California [16], potentially 
resulting in selection bias. However, for 704 Hispanic cases in that study, birthplace 
distributions (US, foreign, unknown) did not differ significantly between those with and 
without available specimens (data not shown). Fourth, estimated nativity via imputation 
could underestimate rates for the foreign-born to the extent that they were undocumented, 
and thus be counted in the cancer registry but not in the census. Fifth, registry-recorded 
Hispanic ethnicity is subject to some misclassification [32] and may undercount Hispanics, 
enhancing ethnic rate differentials [24].
Our study also has several notable strengths. First, the case series is both large enough for 
evaluating HL rates simultaneously by age group, sex, and histologic subtype and for 
allowing evaluation of the joint effects of race and nativity on HL by tumor cell EBV status 
[16]. Second, as cancer registry cases without recorded birthplace are younger, better 
educated, and more likely to be US-born [29–34], our imputation of nativity where missing, 
rather than exclusion or proportional assignment of such cases, eliminates underestimation 
of rates in US-born Hispanics and subsequent attenuation of nativity comparisons [11]. 
Third, use of population-based cancer registry and census data for a relatively ethnically 
homogeneous population of Hispanics assures more precise study findings, given genetic 
admixture among Hispanics [27, 28] and enhances representativeness and generalizability of 
study findings. Fourth, by calculating rates with annual nativity-specific denominators based 
on statistical modeling, we avoided the likely biases associated with applying single-year 
census estimates to a longer time period.
Summary
In the large California Hispanic and white populations, this study was able to detect complex 
variation in HL incidence rates and EBV associations consistent with strong but age-varying 
effects of socioeconomic and related factors on HL incidence. However, persistent rate 
deficits in AYA US-born Hispanics versus whites and higher tumor EBV prevalence for US-
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born Hispanic than for white children and older adults suggest less modifiable aspects of HL 
etiology. The lesser ethnic and nativity variability, and stronger and persistent association of 
EBV, for MC than for NS point to differing etiologies, with a larger component of invariable 
biological influences for the former. The much stronger impact of nativity on HL rates for 
females than for males, particularly in AYAs, highlights underexplored age-varying 
influences of gender on HL occurrence. Together, these findings not only underscore the 
substantial etiologic heterogeneity of HL, but also point to the need for further investigation 
of genetic and hormonal factors that interact with environmental influences associated with 
HL occurrence.
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Fig. 1. 
Age- and sex-specific incidence rates of classical Hodgkin lymphoma (HL) overall and for 
selected histologic subtypes in Hispanics and whites, 1988–2004, California
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Fig. 2. 
Age- and sex-specific incidence rates of classical Hodgkin lymphoma (HL) overall and for 
selected histologic subtypes in US-born and foreign-born Hispanics and whites, 1988–2004, 
California
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